Citation Impact
Citing Papers
Results of a Pivotal Phase II Study of Brentuximab Vedotin for Patients With Relapsed or Refractory Hodgkin's Lymphoma
2012 Standout
The 2016 revision of the World Health Organization classification of lymphoid neoplasms
2016 Standout
Reciprocal Regulation of DUSP9 and DUSP16 Expression by HIF1 Controls ERK and p38 MAP Kinase Activity and Mediates Chemotherapy-Induced Breast Cancer Stem Cell Enrichment
2018 StandoutNobel
Pharmacologic Targeting of Hypoxia-Inducible Factors
2019 StandoutNobel
A RASSF1A-HIF1α loop drives Warburg effect in cancer and pulmonary hypertension
2019 StandoutNobel
JAK Kinase Inhibition Abrogates STAT3 Activation and Head and Neck Squamous Cell Carcinoma Tumor Growth
2015
Hallmarks of Cancer: The Next Generation
2011 Standout
Histone deacetylases (HDACs) as therapeutic target for depressive disorders
2017
HIF Hydroxylase Pathways in Cardiovascular Physiology and Medicine
2015 StandoutNobel
Regulation of carotid body oxygen sensing by hypoxia-inducible factors
2015 StandoutNobel
Cancer treatment and survivorship statistics, 2022
2022 Standout
Targeting JAK kinase in solid tumors: emerging opportunities and challenges
2015
The molecular hallmarks of epigenetic control
2016 Standout
Recent insights into the biology of Hodgkin lymphoma: unraveling the mysteries of the Reed–Sternberg cell
2007
The role of hypoxia in cancer progression, angiogenesis, metastasis, and resistance to therapy
2015 Standout
Precision therapy for lymphoma—current state and future directions
2014
Combination Therapy With Histone Deacetylase Inhibitors (HDACi) for the Treatment of Cancer: Achieving the Full Therapeutic Potential of HDACi
2018
Cell type-specific function of TAK1 in innate immune signaling
2013
TT Viruses: Oncogenic or Tumor-Suppressive Properties?
2008 StandoutNobel
The paradox of autophagy and its implication in cancer etiology and therapy
2009
Hypoxia-Inducible Factors: Master Regulators of Cancer Progression
2016 StandoutNobel
Therapeutic targets in cancer cell metabolism and autophagy
2012
Antimicrobial Autophagy: A Conserved Innate Immune Response in Drosophila
2013 Standout
Macrolides sensitize EGFR-TKI-induced non-apoptotic cell death via blocking autophagy flux in pancreatic cancer cell lines
2015 StandoutNobel
Repertoire of microglial and macrophage responses after spinal cord injury
2011 Standout
Autophagy: Renovation of Cells and Tissues
2011 Standout
Putative mechanisms of antitumor activity of cyano-substituted heteroaryles in HeLa cells
2010
Hypoxia and the extracellular matrix: drivers of tumour metastasis
2014 StandoutNobel
Brentuximab vedotin
2012
REVIGO Summarizes and Visualizes Long Lists of Gene Ontology Terms
2011 Standout
Anchor extension: a structure-guided approach to design cyclic peptides targeting enzyme active sites
2021 StandoutNobel
The JAK/STAT signaling pathway: from bench to clinic
2021 Standout
Targeting the IL-6/JAK/STAT3 signalling axis in cancer
2018 Standout
Epigenetic protein families: a new frontier for drug discovery
2012
Light‐Controlled Histone Deacetylase (HDAC) Inhibitors: Towards Photopharmacological Chemotherapy
2015 StandoutNobel
Autophagy Suppresses RIP Kinase-Dependent Necrosis Enabling Survival to mTOR Inhibition
2012
Hypoxia-inducible factors promote breast cancer stem cell specification and maintenance in response to hypoxia or cytotoxic chemotherapy
2018 StandoutNobel
Autophagy modulation as a potential therapeutic target for diverse diseases
2012 Standout
The hallmarks of cancer
2012 Standout
Autophagy as a target for anticancer therapy
2011
Therapeutic modulators of STAT signalling for human diseases
2013
Indoles as therapeutics of interest in medicinal chemistry: Bird's eye view
2017 Standout
Reduced intensity allogeneic hematopoietic cell transplantation can induce durable remission in heavily pretreated relapsed Hodgkin lymphoma
2011
Inhibition of PI3K/Akt/mTOR pathway by apigenin induces apoptosis and autophagy in hepatocellular carcinoma cells
2018 Standout
Alternatively activated alveolar macrophages in pulmonary fibrosis—mediator production and intracellular signal transduction
2010
Toll-Like Receptor Signaling Pathways
2014 Standout
Regulatory networks defining EMT during cancer initiation and progression
2013 Standout
Panobinostat in lymphoid and myeloid malignancies
2013
Histone deacetylases and cancer
2012
Guidelines on the Use of Therapeutic Apheresis in Clinical Practice – Evidence‐Based Approach from the Writing Committee of the American Society for Apheresis: The Eighth Special Issue
2019 Standout
Hodgkin lymphoma: 2018 update on diagnosis, risk‐stratification, and management
2018
Anthracyclines suppress pheochromocytoma cell characteristics, including metastasis, through inhibition of the hypoxia signaling pathway
2017 StandoutNobel
Expression Pattern of HIF-1α and VEGF Supports Circumferential Application of Scatter Laser for Proliferative Sickle Retinopathy
2016 StandoutNobel
Panobinostat in Patients With Relapsed/Refractory Hodgkin's Lymphoma After Autologous Stem-Cell Transplantation: Results of a Phase II Study
2012
New and emerging HDAC inhibitors for cancer treatment
2014
Romidepsin: A Histone Deacetylase Inhibitor for Refractory Cutaneous T-Cell Lymphoma
2012
Protein kinase A–dependent phosphorylation stimulates the transcriptional activity of hypoxia-inducible factor 1
2016 StandoutNobel
Histone Deacetylase Inhibitors in Clinical Studies as Templates for New Anticancer Agents
2015
The Role of Hypoxia and Exploitation of the Hypoxic Environment in Hematologic Malignancies
2014
Traditional Chinese medicine as a cancer treatment: Modern perspectives of ancient but advanced science
2019 Standout
Hypoxia-inducible factor 1 upregulation of both VEGF and ANGPTL4 is required to promote the angiogenic phenotype in uveal melanoma
2016 StandoutNobel
Modulation of antigen‐presenting cells by HDAC inhibitors: implications in autoimmunity and cancer
2011
Oxygen Sensing, Hypoxia-Inducible Factors, and Disease Pathophysiology
2013 StandoutNobel
Inositol Polyphosphate Multikinase Inhibits Angiogenesis via Inositol Pentakisphosphate-Induced HIF-1α Degradation
2017 StandoutNobel
Combination therapy in combating cancer
2017 Standout
Investigational histone deacetylase inhibitors for non-Hodgkin lymphomas
2010
Hyperplasia and hypertrophy of pulmonary neuroepithelial bodies, presumed airway hypoxia sensors, in hypoxia-inducible factor prolyl hydroxylase-deficient mice
2016 StandoutNobel
Natural product and natural product derived drugs in clinical trials
2014 Standout
HIF-1α and TAZ serve as reciprocal co-activators in human breast cancer cells
2015 StandoutNobel
HDACs and HDAC Inhibitors in Cancer Development and Therapy
2016
BRCA1-IRIS promotes human tumor progression through PTEN blockade and HIF-1α activation
2018 StandoutNobel
Reactive Oxygen Species-Induced Lipid Peroxidation in Apoptosis, Autophagy, and Ferroptosis
2019 Standout
Autophagy and Metabolism
2010 StandoutScience
CutaneousT ‐cell lymphoma: 2016 update on diagnosis, risk‐stratification, and management
2015
The Controversial Role of Human Gut Lachnospiraceae
2020 Standout
Vorinostat suppresses hypoxia signaling by modulating nuclear translocation of hypoxia inducible factor 1 alpha
2017
Regulation of cell proliferation by hypoxia-inducible factors
2015 StandoutNobel
The Double-Edged Sword of Autophagy Modulation in Cancer
2009
Synopsis of Some Recent Tactical Application of Bioisosteres in Drug Design
2011 Standout
Works of Daniela Buglio being referenced
Vorinostat inhibits STAT6-mediated TH2 cytokine and TARC production and induces cell death in Hodgkin lymphoma cell lines
2008
Regulation of HIF-1α signaling and chemoresistance in acute lymphocytic leukemia under hypoxic conditions of the bone marrow microenvironment
2012
Mocetinostat for relapsed classical Hodgkin's lymphoma: an open-label, single-arm, phase 2 trial
2011
Histone deacetylase inhibitors in lymphoma
2010
Temsirolimus downregulates p21 without altering cyclin D1 expression and induces autophagy and synergizes with vorinostat in mantle cell lymphoma
2008
Expression of histone deacetylases in lymphoma: implication for the development of selective inhibitors
2009
Novel small-molecule therapy of Hodgkin lymphoma
2007
The class‐I HDAC inhibitor MGCD0103 induces apoptosis in Hodgkin lymphoma cell lines and synergizes with proteasome inhibitors by an HDAC6‐independent mechanism
2010
The Pan-Deacetylase Inhibitor Panobinostat Downregulates HIF-1α and VEGF and, Synergizes with Everolimus In Hodgkin Lymphoma Cell Lines
2010
Essential role of TAK1 in regulating mantle cell lymphoma survival
2012
Phase I Study of Panobinostat plus Everolimus in Patients with Relapsed or Refractory Lymphoma
2013
HDAC11 plays an essential role in regulating OX40 ligand expression in Hodgkin lymphoma
2011
The JAK inhibitor AZD1480 regulates proliferation and immunity in Hodgkin lymphoma
2011
Isotype-Selective HDAC Inhibitor MGCD0103 Decreases Serum TARC Concentrations and Produces Clinical Responses in Heavily Pretreated Patients with Relapsed Classical Hodgkin Lymphoma (HL).
2007